Given that obeticholic acid, an FXR agonist, did not receive FDA approval due to concerns of potential hepatoxicity and increased risk of gall bladder events, there is dampened enthusiasm to develop an FXR agonist in the treatment of MASH. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.